In a welcome move, Xenon Pharmaceuticals saw its Relative Strength Rating rise from 70 to 76 on Wednesday.
How To Invest In Stocks In Both Bull And Bear Markets
This proprietary rating identifies market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
History reveals that the market's biggest winners often have an RS Rating of over 80 as they launch their largest price moves. See if Xenon Pharmaceuticals can continue to show renewed price strength and hit that benchmark.
While the stock is not near an ideal buy point right now, see if it goes on to form and break out from a proper consolidation.
The company reported 0% EPS growth in its most recent report. Revenue increased -100%.
The company holds the No. 263 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and argenx ADR are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
